GlassScriptPhysician profile
Ruggero Serafini
NPI 1306084561
$1,405.51
in general payments reported to CMS, 2019-2025
33 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.44 · 2022: $139 · 2023: $548 · 2024: $490 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $131.38 | 2022-2025 | |
| Ucb, INC. | $130.47 | 2023-2024 | Fintepla, Briviact |
| Sumitomo Pharma America, INC. | $128.76 | 2023-2024 | Aptiom |
| Neurelis, INC. | $108.58 | 2023-2024 | Valtoco |
| Abbvie INC. | $88.46 | 2023-2025 | Ubrelvy |
| Sk Life Science, INC. | $87.95 | 2022-2025 | Xcopri |
| Catalyst Pharmaceuticals, INC. | $62.16 | 2023-2024 | Fycompa |
| Otsuka America Pharmaceutical, INC. | $54.14 | 2023-2024 | Rexulti |
| Eisai INC. | $51.06 | 2023-2024 | |
| Mdd US Operations, LLC | $51.00 | 2023-2024 | Myobloc, Apokyn, Xadago |
| Biogen, INC. | $48.35 | 2023-2024 | Tysabri, Vumerity, Plegridy |
| Neurocrine Biosciences, INC. | $43.55 | 2023-2025 | Ongentys, Ingrezza |
| Ge Healthcare | $40.70 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $36.22 | 2022 | |
| Kyowa Kirin, INC. | $27.67 | 2023 | Nourianz |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $26.88 | 2025 | Cholbam |
| Azurity Pharmaceuticals, INC. | $26.84 | 2025 | Zonisade |
| Astrazeneca Pharmaceuticals LP | $24.22 | 2024 | Wainua |
| Pfizer INC. | $20.99 | 2025 | |
| Tg Therapeutics, INC. | $19.86 | 2024 | |
| Genentech USA, INC. | $19.27 | 2023 | Ocrevus |
| Acadia Pharmaceuticals INC | $19.03 | 2023 | Nuplazid |
| Lilly USA, LLC | $18.80 | 2024 | Reyvow, Emgality |
| Philips North America LLC | $17.65 | 2023 | |
| Emd Serono, INC. | $16.74 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.82 | 2025 | Austedo Xr |
| Abbott Laboratories | $14.80 | 2024 | Infinity |
| Amgen INC. | $14.58 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.44 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2024 | Hyqvia |
| Lundbeck LLC | $12.43 | 2022 | |
| Impel Pharmaceuticals LLC | $7.01 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruggero Serafini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.